Responses
Novel treatment (new drug/intervention; established drug/procedure in new situation)
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 1 May 2009Loss of heterozygosity in SDHB locus on chromosome 1 in a subject with a metastatic papillary type IA recent case report in this journal presented the case of a subject with an SDHB mutation who developed a metastatic type II papillary renal cell carcinoma which therapeutically responded to the tyrosine kinase inhibitor, sunitinib 1 2. SDHB germline mutations account for the familial paraganglioma syndrome type 4 (PGL-4) which is characterised by predominantly extra-adrenal paragangliomas with high malignant potential 2. SDHB...Show MoreConflict of Interest:
None declared.